<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Catalyst Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc</link>
<description>Latest news and press releases for Catalyst Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:03:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/catalyst-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683558d478dffbe2df0eac6a.webp</url>
<title>Catalyst Pharmaceuticals Inc</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc</link>
</image>
<item>
<title>Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-may-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-may-11-2026</guid>
<pubDate>Tue, 28 Apr 2026 12:03:00 GMT</pubDate>
<description>The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ETCORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2026 financial results after the market close on Monda</description>
</item>
<item>
<title>Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-to-showcase-realworld-findings-in-duchenne-muscular-dystrophy-and-host-vamorolone-focused-symposium-at-the-2026-mda-clinical-and-scientific-conference-30</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-to-showcase-realworld-findings-in-duchenne-muscular-dystrophy-and-host-vamorolone-focused-symposium-at-the-2026-mda-clinical-and-scientific-conference-30</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical</description>
</item>
<item>
<title>Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-reports-record-fourth-quarter-and-record-full-year-2025-financial-results-and-provides-2026-financial-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-reports-record-fourth-quarter-and-record-full-year-2025-financial-results-and-provides-2026-financial-guidance</guid>
<pubDate>Wed, 25 Feb 2026 21:07:00 GMT</pubDate>
<description>Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Ne</description>
</item>
<item>
<title>Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-to-participate-in-the-barclays-28th-annual-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-to-participate-in-the-barclays-28th-annual-global-healthcare-conference</guid>
<pubDate>Tue, 24 Feb 2026 13:03:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare C</description>
</item>
<item>
<title>Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-report-fourth-quarter-130300054</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-report-fourth-quarter-130300054</guid>
<pubDate>Wed, 11 Feb 2026 13:03:00 GMT</pubDate>
<description>The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ETCORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2025 financial results af</description>
</item>
<item>
<title>Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-receives-prestigious-ranking-130300191</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-receives-prestigious-ranking-130300191</guid>
<pubDate>Thu, 08 Jan 2026 13:03:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list</description>
</item>
<item>
<title>The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/university-notre-dame-and-catalyst-pharmaceuticals-host-inaugural-catalyst-advocacy</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/university-notre-dame-and-catalyst-pharmaceuticals-host-inaugural-catalyst-advocacy</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive CORAL GABLES, Fla., Jan. 05, 2026</description>
</item>
<item>
<title>Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-44th-annual-jp-morgan-healthcare-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-44th-annual-jp-morgan-healthcare-conference-2025</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage</description>
</item>
<item>
<title>Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-bank-america-cns-therapeutics-virtual-conference</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-bank-america-cns-therapeutics-virtual-conference</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage</description>
</item>
<item>
<title>Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-recognized-one-north-americas-fastest-growing-companies-2025</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-recognized-one-north-americas-fastest-growing-companies-2025</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals,</description>
</item>
<item>
<title>Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-citis-2025-global-healthcare-conference-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-citis-2025-global-healthcare-conference-2025-11</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage</description>
</item>
<item>
<title>Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA®</description>
</item>
<item>
<title>Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-recognized-among-biospace-2026-best-places-work-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-recognized-among-biospace-2026-best-places-work-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage</description>
</item>
<item>
<title>Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-jefferies-global-healthcare-conference-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-jefferies-global-healthcare-conference-2025-11</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage</description>
</item>
<item>
<title>Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-report-third-quarter-2025-financial-results-november-5-2025</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-report-third-quarter-2025-financial-results-november-5-2025</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-announces-presentations-upcoming-scientific-conferences-2025</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-announces-presentations-upcoming-scientific-conferences-2025</guid>
<pubDate>Thu, 09 Oct 2025 04:00:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company</description>
</item>
<item>
<title>Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/santhera-announces-approval-in-canada-for-agamreer-vamorolone-as-a-treatment-for-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/santhera-announces-approval-in-canada-for-agamreer-vamorolone-as-a-treatment-for-duchenne-muscular-dystrophy</guid>
<pubDate>Fri, 03 Oct 2025 05:00:00 GMT</pubDate>
<description>Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for th</description>
</item>
<item>
<title>Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-announces-200-million-share-repurchase-program-2025-10-01</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-announces-200-million-share-repurchase-program-2025-10-01</guid>
<pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage</description>
</item>
<item>
<title>Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/santhera-secures-chf-20-million-growth-funding-to-accelerate-global-agamreer-rollout</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/santhera-secures-chf-20-million-growth-funding-to-accelerate-global-agamreer-rollout</guid>
<pubDate>Tue, 23 Sep 2025 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR Highlights: Santhera secures approximately CHF 20 million of additional funding from existing investors Highbridge and R-Bridge to accelerate global rolloutDemand for AGAMREE® (vamorolone) in US/China ahead of plan; increased inventory needs and launch timing shifts drive need for incremental growth capital Pratteln, Switzerland, September 23, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces new financing agreements with R-Bridge, an affiliat</description>
</item>
<item>
<title>Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-upcoming-investor-conferences-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/catalyst-pharmaceuticals-inc/news/catalyst-pharmaceuticals-participate-upcoming-investor-conferences-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage</description>
</item>
</channel>
</rss>